Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
RENOTORCH
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
- NCT04394975 ↗
- Completed
- Shanghai Junshi Bioscience Co., Ltd.
- Deep
We haven't built an HCP commentary report on RENOTORCH (toripalimab plus axitinib in first-line unresectable or metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RENOTORCH so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| YouTube | 4 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
- Interventions
- Biological : Toripalimab Drug: Axitinib; sunitinib
- Arms
- Test group · Experimental
- Control group · Active comparator
- Enrollment
- 421
- Primary outcomes
- PFS assessed by IRC per RECIST 1.1.
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Start
- Aug 20, 2020
- Primary completion
- Apr 2, 2024
- Results posted
- No
- Registry record
- NCT04394975 · updated Nov 28, 2025
Publications
linked from the registry- Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21. PubMed 37872020